News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Supernus Pharmaceuticals Prices IPO at $5, Raising $50 Million



5/1/2012 7:19:38 AM

ROCKVILLE, Md., Apr 30, 2012 (GlobeNewswire via COMTEX) -- Supernus Pharmaceuticals, Inc. (the "Company") today announced the initial public offering of 10,000,000 shares of its common stock at a price of $5.00 per share. The Company's shares are expected to begin trading on The NASDAQ Global Market on Tuesday, May 1, 2012 under the trading symbol "SUPN." The underwriters have a 30 day option to purchase up to an additional 1,500,000 shares from the Company.

Citigroup and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Cowen and Company, LLC and Stifel Nicolaus Weisel are acting as co-managers.

The offering is being made only by means of a prospectus. When available, a copy of the prospectus related to the offering may be obtained by contacting: Citigroup at Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220, Attention: Prospectus Department, telephone: 1-800-831-9146 or email: batprospectusdept@citi.com, or Piper Jaffray & Co. at 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, telephone: 1-800-747-3924 or e-mail: prospectus@pjc.com.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The company is developing several product candidates in neurology and psychiatry to address large market opportunities in epilepsy and ADHD including ADHD patients with impulsive aggression. These product candidates include SPN-538 (extended-release topiramate) and SPN-804 (extended-release oxcarbazepine) for epilepsy, SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Supernus Pharmaceuticals, Inc.

CONTACT: Jack Khattar, President & CEO

Gregory S. Patrick, Vice President and CFO

Supernus Pharmaceuticals, Inc.

Tel: (301) 838-2591




comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES